Peer-reviewed veterinary case report
Robenacoxib reduces pain and inflammation in dogs with acute joint
By Schmid, V B et al.·Published in Journal of veterinary pharmacology and therapeutics·2010·Novartis Centre de Recherche Santé·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog.
- Species:
- dog
Plain-English summary
A group of dogs with acute joint inflammation were treated with a new pain relief medication called robenacoxib to see how well it worked compared to a common pain reliever, meloxicam. The dogs showed significant improvement in weight-bearing, pain, and swelling after receiving robenacoxib, especially at doses of 1-2 mg/kg. The results indicated that robenacoxib was at least as effective as meloxicam in reducing pain and inflammation without affecting other important blood markers. This suggests that robenacoxib could be a good option for managing joint pain in dogs.
People also search for: dog joint pain relief · robenacoxib for dogs · meloxicam dosage for dogs
Abstract
The objectives of this study were to establish dose-response and blood concentration-response relationships for robenacoxib, a novel nonsteroidal anti-inflammatory drug with selectivity for inhibition of the cyclooxygenase (COX)-2 isoenzyme, in a canine model of synovitis. Acute synovitis of the stifle joint was induced by intra-articular injection of sodium urate crystals. Robenacoxib (0.25, 0.5, 1.0, 2.0 and 4.0 mg/kg), placebo and meloxicam (0.2 mg/kg) were administered subcutaneously (s.c.) 3 h after the urate crystals. Pharmacodynamic endpoints included data from forceplate analyses, clinical orthopaedic examinations and time course of inhibition of COX-1 and COX-2 in ex vivo whole blood assays. Blood was collected for pharmacokinetics. Robenacoxib produced dose-related improvement in weight-bearing, pain and swelling as assessed objectively by forceplate analysis (estimated ED(50) was 1.23 mg/kg for z peak force) and subjectively by clinical orthopaedic assessments. The analgesic and anti-inflammatory effects of robenacoxib were significantly superior to placebo (0.25-4 mg/kg robenacoxib) and were non-inferior to meloxicam (0.5-4 mg/kg robenacoxib). All dosages of robenacoxib produced significant dose-related inhibition of COX-2 (estimated ED(50) was 0.52 mg/kg) but no inhibition of COX-1. At a dosage of 1-2 mg/kg administered s.c., robenacoxib should be at least as effective as 0.2 mg/kg of meloxicam in suppressing acute joint pain and inflammation in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20444036/